Understanding the impact of medications for opioid use disorder on health related quality of life (QOL) may help to explain why few individuals with legal involvement remain in treatment, specifically those receiving opioid antagonists. QOL is an established predictor of treatment retention and has been shown to improve with some treatment for opioid use disorder. Yet limited research has examined QOL with opioid antagonists. We examined the impact of extended release naltrexone (XR-NTX) on QOL and retention in treatment in a randomized, multi-site trial of individuals with legal involvement.
Methods
The participants were 308 community-dwelling adults with current or recent legal involvement with opioid dependence at five site across United States. They were randomized to receive XR-NTX or treatment as usual for 6 months. QOL was measured every 2 weeks using Euro QOL individual items, summary index score, and health state today metric.
Results
No significant difference in QOL scores were observed between the two groups at the completion of active treatment or on follow up at 52 and 78 weeks. There were no time effects of treatment on scores. Contrary to expectation, baseline and average QOL did not predict retention in treatment.
Conclusion
In contrast to prior research, our findings did not demonstrate significant changes (improvements or decreases) in QOL associated with XR-NTX treatment. Clinicians may consider that individuals receiving XR-NTX may not experience changes in perceived well-being in response to treatment and consider discussing with patients that they may not necessarily perceive improvement in their QOL. This may help to ground patient's expectations about the effects of treatment and potentially reduce attrition from treatment with opioid antagonists.
BinswangerIA, SternMF, DeyoRA, . Release from prison-a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–165.
2.
BinswangerIA, BlatchfordPJ, MuellerSR, SternMF.Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
3.
FazelS, BainsP, DollH.Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–191.
4.
FriedmannPD, HoskinsonR, GordonM, . Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9–18.
5.
MitchellSG, WilletJ, MonicoLB, . Community correctional agents’ views of medication-assisted treatment: examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016;37(1):127–133.
6.
MaltaM, VaratharajanT, RussellC, PangM, BonatoS, FischerB.Opioid-related treatment, interventions, and outcomes among incarcerated persons: a systematic review. PLoS Med. 2019;16(12):e1003002.
7.
SharmaA, O'GradyKE, KellySM, GryczynskiJ, MitchellSG, SchwartzRP.Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abuse Rehabil. 2016;7:27–40.
8.
ChandlerRK, FletcherBW, VolkowND.Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009;301(2):183–190.
9.
RobertsonAG, SwartzMS.Extended-release naltrexone and drug treatment courts: policy and evidence for implementing an evidence-based treatment. J Subst Abuse Treat. 2018;85:101–104.
BahjiA, CarloneD, AltomareJ.Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis. Addiction. 2020;115(8):1413–1425.
12.
FriedmannPD, WilsonD, HoskinsonRJr., PoshkusM, ClarkeJG.Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. J Subst Abuse Treat. 2017.;85:45–48
13.
LincolnT, JohnsonBD, McCarthyP, AlexanderE.Extended-release naltrexone for opioid use disorder started during or following incarceration. J Subst Abuse Treat. 2017;85:97–100.
14.
Centers for Disease Control and Prevention.Measuring Healthy Days: Population Assessment of Health-Related Quality of Life. Atlanta, GA: CDC; 2000.
15.
LandSR, WalcottFL, LiuQ, WickerhamDL, CostantinoJP, GanzPA.Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/NSABP trial P-1. JNCIJ. 2016;108(4):djv365.
16.
YounossiZM, StepanovaM, HenryL, NaderF, YounossiY, HuntS.Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine. 2016;95(28):e4151.
17.
MarcellinP, ChoustermanM, FontangesT, . Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study: real-life adherence to HCV treatment. Liver Int. 2011;31(4):516–524.
18.
LaudetAB, BeckerJB, WhiteWL.Don't wanna go through that madness no more: quality of life satisfaction as predictor of sustained remission from illicit drug misuse. Subst Use Misuse. 2009;44(2):227–252.
19.
TiffanyST, FriedmanL, GreenfieldSF, HasinDS, JacksonR.Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders. Addiction. 2012;107(4):709–718.
20.
LaudetAB.The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract. 2011;6(1):44–55.
21.
BrayJW, AdenB, EggmanAA, . Quality of life as an outcome of opioid use disorder treatment: a systematic review. J Subst Abuse Treat. 2017;76:88–93.
22.
MullerAE, SkurtveitS, ClausenT.Many correlates of poor quality of life among substance users entering treatment are not addiction-specific. Health Qual Life Outcomes. 2016;14:39.
23.
De MaeyerJ, VanderplasschenW, LammertynJ, van NieuwenhuizenC, SabbeB, BroekaertE.Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatment. Qual Life Res. 2011;20(1):139–150.
24.
RheeTG, RosenheckRA.Comparison of opioid use disorder among male veterans and non-veterans: disorder rates, socio-demographics, co-morbidities, and quality of life. Am J Addict. 2019;28(2):92–100.
25.
KarowA, VertheinU, PukropR, . Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. Subst Use Misuse. 2011;46(6):705–715.
26.
PonizovskyAM, MargolisA, HeledL, RoscaP, RadomislenskyI, GrinshpoonA.Improved quality of life, clinical, and psychosocial outcomes among heroin-dependent patients on ambulatory buprenorphine maintenance. Subst Use Misuse. 2010;45(1–2):288–313.
27.
WangPW, WuHC, YenCN, . Change in quality of life and its predictors in heroin users receiving methadone maintenance treatment in Taiwan: an 18-month follow-up study. Am J Drug Alcohol Abuse. 2012;38(3):213–219.
28.
TranBX, OhinmaaA, DuongAT, . Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. Qual Life Res. 2012;21(4):613–623.
29.
MitchellSG, GryczynskiJ, SchwartzRP, . Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015;47(2):149–157.
30.
PonizovskyAM, GrinshpoonA.Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631–642.
31.
NosykB, GuhDP, SunH, . Health related quality of life trajectories of patients in opioid substitution treatment. Drug Alcohol Depend. 2011;118(2–3):259–264.
32.
FriedmannPD, WilsonD, NunesEV, . Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?J Subst Abuse Treat. 2018;85:61–65.
33.
EarleyPH, ZummoJ, MemisogluA, SilvermanBL, GastfriendDR.Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence. J Addict Med. 2017;11(3):224–230.
34.
SaxonAJ, AkermanSC, LiuCC, SullivanMA, SilvermanBL, VocciFJ.Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's cost and treatment outcomes registry. Addiction. 2018;113(8):1477–1487.
35.
LaudetAB, StanickV.Predictors of motivation for abstinence at the end of outpatient substance abuse treatment. J Subst Abuse Treat. 2010;38(4):317–327.
36.
GarnerBR, ScottCK, DennisML, FunkRR.The relationship between recovery and health-related quality of life. J Subst Abuse Treat. 2014;47(4):293–298.
37.
Association AP.Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, DC: American Psychiatric Association2013.
38.
LeeJD, FriedmannPD, KinlockTW, . Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–1242.
39.
HerdmanM, GudexC, LloydA, . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736.
40.
NosykB, SunH, GuhDP, . The quality of eight health status measures were compared for chronic opioid dependence. J Clin Epidemiol. 2010;63(10):1132–1144.
41.
OaksZ, StageA, MiddletonB, FaraoneS, JohnsonB.Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov Med. 2018;26(144):197–206.
42.
BoltonMJ, ChapmanBP, Van MarwijkH.Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13(1):e232502.
43.
ParkerCE, NguyenTM, SegalD, MacDonaldJK, ChandeN.Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018;4:CD010410.
44.
YoungerJ, NoorN, McCueR, MackeyS.Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538.
45.
PattenDK, SchultzBG, BerlauDJ.The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389.
